Endometrial Cancer Conservative Treatment (E.C.Co). A Multicentre Archive
Status unconfirmed
Conditions studied: Endometrial Cancer
In brief
Approximately one fourth of cases of endometrial cancer (EC) are diagnosed in premenopausal women, of whom approximately 40% wish to preserve their fertility. When arising in young women, EC usually presents with favorable prognostic features, as a focal, well differentiated endometrioid tumor, with minimal or absent myometrial invasion. This profile corresponds to the Type 1 EC, which correlates with the estrogen/progesterone receptor positive (ER+/PR+) pattern. On the other hand, these patients frequently present with clinical signs of a hyperestrogenism (chronic anovulation, infertility, obesity). Primary progestin therapy has been demonstrated to be effective in early well differentiated tumors and in poor operative candidates with response rates ranging from 58-100%.Currently, the therapeutic approach to an early stage EC consists of a staging laparotomy/laparoscopy, including a total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO), peritoneal washings, and lymphadenectomy (pelvic and aortic), depending on the pathological risk profile pre- and intraoperatively determined. Therefore, the current standard of surgical approach is preclusive of fertility. The worldwide experience and data on conservative management of EC are, however, still limited. Most of reports based on cases retrospectively collected, harboring potential methodological bias, using different treatments and drugs, and with insufficient follow-up. Some systematic reviews have been published in the last decade, trying to summarize the literature data. Therapeutic results seem to be promising with a regression rate of approximately 75% and relapse occurring in 25-40% of cases, with anecdotical reports of deaths of disease (DOD). The fertility outcome was, however, not satisfying with about 30% pregnancy rate in patients attempting to conceive, and an overall low rate of assisted reproductive techniques (ART) despite the subfertile clinical profile.Therefore, there is a need for a prospective, multicentre cooperative project able to systematically collect data from consecutive patients treated according to defined (not necessarily identical) protocols, concerning the oncological, as well as, the obstetrical outcomes. Moreover, this project could represent the "template" in which a pretreatment fertility counseling, psychological support, and definitive surgery are routinely included according to shared criteria.
Key facts
- Study ID
- NCT04290299
- Run by
- National Cancer Institute, Naples
- People needed
- 100
- Starts
- 2015-09-15
- Expected to finish
- 2025-04-08
- Last updated by the study team
- 2021-10-13
Who can join
Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Informed consent to personal data processing
- Existence of an IRB-approved local protocol that allows conservative treatment to be performed or statement that such treatment is considered as a standard (please note that such protocols should be shared with the database owner National Cancer Institute of Naples).
Where it is running
- Cooperative Ovarian Cancer Group (COGI) — Stanford, California, United States (enrolling)
- ANZGOG - Australia and New Zealand Gynecological Oncology Group — Sydney, Australia (enrolling)
- AGO-AUST Arbeitsgemeinschaft Gynaekologische Onkologie — Vienna, Austria (enrolling)
- EORTC - European Organization for Research and Treatment of Cancer — Brussels, Belgium (enrolling)
- NCIC Clinical Trials Group (Canadian Cancer Society Research Institute) — Ottawa, Canada (enrolling)
- PMHC (Princess Margaret Hospital Consortium) — Toronto, Canada (enrolling)
- SGOG (Shanghai Gynecologic Oncology Group) — Shanghai, China (enrolling)
- NSGO (Nordic Society of Gynecologic Oncology) — Copenhagen, Denmark (enrolling)
- GINECO - Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens — Paris, France (enrolling)
- AGO-De Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom — Berlin, Germany (enrolling)
- NOGGO (Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie) — Berlin, Germany (enrolling)
- ICORG - Ireland Cooperative Oncology Research Group — Dublin, Ireland (enrolling)
- MITO (Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies) — Naples, Italy (enrolling)
- GOTIC - Gynecologic Oncology Trial and Investigation Consortium — Katō, Japan (enrolling)
- JGOG - Japanese Gynecologic Oncology Group — Tokyo, Japan (enrolling)
- DGOG - Dutch Gynecologic Oncology Group — Amsterdam, Netherlands (enrolling)
- KGOG - Korean Gynecologic Oncology Group — Seoul, South Korea (enrolling)
- GEICO - Grupo Espanol de Investigacion en Cancer de Ovario — Madrid, Spain (enrolling)
- SGCTG (Scottish Gynaecological Cancer Trials Group) — Edinburgh, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.